Vertex Pharmaceuticals

VRTX · NASDAQ

$514.65+$12.70 (+2.53%)TodayMarket closed · Oct 20, 7:59 PM ET

Prev close $501.95

VRTX analyst rating

BuyConsensus of 26 analysts over the last 12 months. 81% rate it a buy.

Strong buy0
Buy21
Hold4
Underperform1
Sell0

12-month price target · 31 analysts

Average $583.37 (+13.4% upside)

Low: $353.50
Now: $514.65
High: $705.60

Upgrades and downgrades

The latest rating actions, newest first

VRTX analyst upgrades, downgrades and rating actions
Firm	Date	Action	Rating	Price target	Hit rate
RBC Capital	Oct 8, 2026	Maintains	Outperform	$570.00 → $576.00	44%
UBS	Sep 28, 2026	Maintains	Buy	$585.00 → $615.00	53%
JP Morgan	Sep 11, 2026	Initiates	Overweight	$515.00 → $560.00	57%
Morgan Stanley	Sep 2, 2026	Initiates	Overweight	$665.00	63%
Truist Securities	Aug 5, 2026	Maintains	Buy	$560.00 → $565.00	36%
Barclays	Aug 5, 2026	Maintains	Overweight	$615.00 → $617.00	45%
TD Cowen	Aug 4, 2026	Maintains	Buy	$525.00 → $550.00	56%
Cantor Fitzgerald	Aug 4, 2026	Maintains	Overweight	$590.00 → $595.00	64%
Canaccord Genuity	Aug 4, 2026	Maintains	Hold	$436.00 → $442.00	41%
UBS	Jul 13, 2026	Maintains	Buy	$545.00 → $585.00	53%

The case for and against

Updated Aug 25, 2026

Bull case

Vertex Pharmaceuticals is well-positioned in the healthcare industry due to its strong commercial position in cystic fibrosis treatment and promising pipeline programs, including gene-editing therapy for beta thalassemia and sickle-cell disease, and a potential functional cure for type 1 diabetes. Additionally, the company's diversified portfolio and potential pipeline successes, along with a commitment to sustainability, provide further potential upside for the stock. Despite some minor setbacks, Vertex's continued growth and widespread market acceptance make it a promising investment opportunity.

Bear case

Vertex Pharmaceuticals is facing near-term catalyst risks, but with a successful Q1, reaffirmation of pove's safety, and low expectations for future pipeline events, the fundamental valuation gap should close. With promising pipeline assets in the renal space and a strong CF franchise, the company has significant potential for diversification and continued revenue growth. However, any setbacks in these key pipeline programs could pose a risk to the company's stock performance.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.